GSK acquires rights to Syndivia's antibody-drug conjugate for prostate cancer

GSK plc announced on October 27, 2025, an agreement granting it exclusive worldwide rights to develop and commercialize a preclinical antibody-drug conjugate (ADC) for the treatment of prostate cancer from Syndivia. This acquisition is a significant expansion of GSK's oncology strategy and its existing prostate cancer program.

Metastatic castration-resistant prostate cancer (mCRPC) remains a substantial health burden for men, with a critical need for novel targeted treatments. Approximately 1.4 million men worldwide are diagnosed with prostate cancer annually, and 10-20% develop advanced disease within five years.

The novel ADC utilizes Syndivia's GeminiMab conjugation technology. Preclinical studies have demonstrated enhanced anti-tumor activity and a promising safety profile. This type of targeted therapy has been a gap in available treatments and could offer a more accessible treatment option in community settings.

GSK states that the acquisition complements the company's prostate cancer pipeline, which already includes the B7H3-targeted ADC, GSK’227. The company is developing various ADC technologies, small molecules, and T-cell engagers for different forms of prostate cancer.

Under the terms of the agreement, Syndivia will receive an upfront payment and success-based development and commercial milestone payments up to a total of £268 million. Syndivia will also receive tiered royalties on future worldwide product sales. GSK will assume full responsibility for the development, manufacturing, and global commercialization of the ADC program.